High-risk patients who meet criteria for PCSK9 inhibitors are still being denied access to treatment.

37,138 Americans with risk factors were denied potentially life-saving medicine.

38% Prior statin use
35% Cardiovascular disease
31% Familial hypercholesterolemia
37% Heart attack or stroke

In 2018

26% Of Commercial Plans Denied ALL PCSK9 Claims

Even though the medicine can reduce:
- Cholesterol by up to 60%
- Heart attack risk by 27%
- Stroke risk by 21%
- Risk of death by 15%

These national health plans denied patients their physician-prescribed PCSK9 inhibitor the most:

Federal Employee Benefit Plan: 76%
UnitedHealth Group: 72%
Express Scripts: 67%
CVS Health: 54%

*All plans had more than 3,000 claims

In 2018

PARTNERSHIP TO ADVANCE Cardiovascular Health

1: Harvard Health Blog 2: American College of Cardiology